Descartes-08 treatment for children, teens, and young adults with select autoimmune diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1/2 interventional trial testing Descartes-08 in patients aged 12 and older with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, or juvenile dermatomyositis. The trial focuses on safety and tolerability while also looking for early signs of clinical benefit in participants with moderate disease and a history of systemic treatment. Participants must meet specific laboratory and clinical criteria and provide informed consent (or parental/guardian consent as appropriate). Study visits will occur at participating clinical sites in Washington, D.C. and St. Louis and will include medical monitoring and laboratory testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least age 12
* definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
* Signs and symptoms of moderate disease
* History of systemic treatment
* Parent/Guardian/Patient must be able to give written informed consent

Exclusion Criteria:

* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient;
* Abnormal PT/INR or PTT increased \> 1.5-fold or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant; or in patients who have been on stable doses of anticoagulation therapy for more than 6 months of VTE diagnosis; or in patients on stable doses of anticoagulation therapy for at least 8 weeks of atrial fibrillation diagnosis; these conditions will not be exclusionary unless, in the investigator's opinion, they make participation in the study unsafe);
* ANC \< 1000 cells/microliter ;
* Hemoglobin \< 8.0 g/dL ;
* Platelets \< 50,000/mm3 (NOTE: platelet transfusions are permissible);
* ALT and/or AST with GGT ≥ 3× upper limit of normal
* Creatine Clearance less than 30mL/min /1.73 m2;
* History of primary immunodeficiency, organ, or allogeneic bone marrow transplant;
* Patients must be seronegative for hepatitis B surface antigen;
* Patients must be seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patients must be tested for the presence of viremia by RT-PCR and must be HCV RNA negative;
* History of positive HIV or positive HIV at screening;
* Active tuberculosis or positive QuantiFERON test at screening;
* Any other laboratory abnormality that, in the opinion of the investigator, may jeopardize the subject's ability to participate in the study; 23. Any active significant cardiac or pulmonary disease not related to the primary indication as determined by principal investigator and medical monitor Note: Patients with asthma and COPD controlled with inhaled medications are allowed; 24. Any arterial or venous thromboembolic events in the past 3 months; 25. History of malignancy that required treatment in the past 3 years except for successfully-treated squamous cell and/or basal cell carcinoma of the skin and/or breast or colon cancer that is surgically removed and did not require adjuvant chemotherapy or radiotherapy; 26. Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer); 27. Receipt of a live vaccination within 4 weeks prior to baseline (Day 1) or intent to receive live vaccination during the study (Note: mRNA-based vaccines such as those against SARS-CoV-2 are not considered live; likewise, the Janssen Covid-19 vaccine is not live); 28. History of significant recurrent infections or any active infection that may interfere with the patient's participation in the opinion of the investigator; 29. Any known psychiatric illness that may interfere with the patient's participation in the study in the opinion of the investigator.

Where it's running

• H01- Children's National Hospital
  Washington D.C., District of Columbia, United States Recruiting
• H03- Washington University School of Medicine
  St Louis, Missouri, United States Recruiting
• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Study coordinator: Cartesian Clinical Trials
• Email: trials@cartesiantx.com
• Phone: 617-231-8102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dermal priming to boost flu vaccine response in people on B cell depletion

  This study tests whether applying a topical cream with imiquimod on the skin around vaccination can boost the body’s response to the flu shot in people who are receiving B cell–depleting therapy.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07925996

• Gyrotonic exercise for adolescents with lupus who survived intensive care

  This study tests whether a Gyrotonic exercise program can help teenagers with childhood-onset lupus who recently survived an intensive care stay and may have lingering post-ICU symptoms.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07833020

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• Obinutuzumab beta with low-dose steroids in new-onset ANCA-associated glomerulonephritis

  This study tests whether adding Obinutuzumab beta to a rapid-tapering glucocorticoid plan can help people with new-onset ANCA-associated glomerulonephritis see if they achieve remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07746180

• MTS109 treatment for refractory autoimmune diseases

  This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07526350

• Patient-rooted insights to shape myositis science

  This global project asks people living with myositis (and their care partners) to share experiences and rank research questions so the community can see which issues matter most.

  Recruiting Myositis International Health & Research Collaborative Alliance Foundation · New Orleans, Louisiana · NCT07374107

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.